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Therapeutic use of cannabinoids, the main active ingredients of Cannabis sativa L.,
is often hindered by their limited bioavailability and undesirable psychoactivity. We
conducted an observational study in December 2016 and another one in February
2018 to investigate respectively: (i) the effectiveness of Trokie R© lozenges, a standardized
formulation containing cannabis extracts, to deliver cannabinoids via buccal absorption
and (ii) its long-term safety. Participants were members of the Palliative Care Corporation
health clinic, registered California cannabis patients, and had a diagnosis of chronic
non-cancer pain. For the effectiveness study, 49 participants were asked to self-report
pain perception before and after 1–12 weeks of taking Trokie R© lozenges, using an 11-
point pain intensity numeric rating scale (PI-NRS). A mean reduction in PI-NRS score
of 4.9 ± 2.0 points was observed. Onset of analgesia typically varied between 5 and
40 min, which seems consistent with, at least partial, buccal absorption. In the safety
study, 35 participants were asked to complete a questionnaire about adverse events
(AEs) associated with Trokie R© lozenges. AEs were reported by 16 subjects (46%), the
most common being dizziness/unsteadiness (N = 7), bad taste (N = 5), and throat
irritation/dry mouth (N = 4). None of the self-reported AEs resulted in a serious medical
situation and most of them had limited impact on daily functions. Despite the AEs,
90% of participants reported being “satisfied” or “very satisfied” with the product. These
observations suggest that buccal administration of standardized extracts via Trokie R©
lozenges may represent an efficacious and safe approach to cannabis administration.
Keywords: cannabis, effectiveness, safety, adverse events, trokie R© lozenges, standardized, buccal
administration, polyethylene glycol
INTRODUCTION
In recent years, many countries have passed legislation permitting the use of cannabis for medical
reasons. This has given patients access to both herbal material and cannabis-based products,
bypassing the strict regulatory procedures that usually apply to pharmaceutical development
(Fitzcharles and Eisenberg, 2018). Further, legalization of cannabis for recreational purposes
Abbreviations: AEs, Adverse events; CBD, Cannabidiol; IRB, institutional review board; PCC, Palliative Care Corporation;
PEG, polyethylene glycol; PI-NRS, Pain intensity numeric rating scale; THC,19-tetrahydrocannabinol.
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in several states of the Union as well as in internationally-relevant
countries, such as Canada, conferrers cannabis an intriguing
dual status, both as a pharmaceutical substance and a mere
commodity, thus creating a complex regulatory scenario.
Manufacturers of cannabis products, irrespective of their
purpose, are met alike with the limitations that the lipophilic
nature of cannabinoids, the main active substances in Cannabis
sativa L., poses to their absorption and distribution in the
human body (Huestis, 2005). Moreover, the psychoactive effects
induced by 19-tetrahydrocannabinol (THC), the primary active
ingredient present in cannabis, need to be: (i) minimized
for patients to maximize the therapeutic index of cannabis
medications, and (ii) carefully controlled for adult consumers
in order to reduce both the risk of acute intoxication and the
impact on public health and safety. Economic reasons also play
a role since increasing the bioavailability of cannabinoids could
allow for a reduction in the amount of active ingredient per dose,
thus lowering the cost of the final product. Current efforts to
achieve efficient, reliable dosing aim at exploring different routes
of administration (e.g., pulmonary, oral, mucosal, transdermal)
and delivery vectors (e.g., inhaling powders, nanovehicles) to
optimize the pharmacokinetic profile of cannabinoids (van
Drooge et al., 2005; Conte et al., 2017). Given the current
lack of regulation in the medical and adult markets, cannabis-
based products are readily available for the general population
to acquire and consume without medical supervision. For
some researchers, this represents a waste of valuable clinical
information that could be extremely useful if adequately
collected.
Sativex R© (USAN: nabiximols), an ethanol-based oromucosal
preparation with 2.7 mg of THC and 2.5 mg cannabidiol
(CBD) per spray, was the first cannabis product to attain
regulatory approval as a pharmaceutical in 29 countries, having
met the required standards of safety, efficacy and consistency
(MacCallum and Russo, 2018). Nevertheless, it presents some
adverse events (AEs) associated either with the pharmacology
of cannabinoids (e.g., dizziness, drowsiness, dry mouth) or
the detrimental effects of alcohol upon the oral mucosa
(Scully, 2007). An alternative to ethanol could be muco-
inert polymeric coatings such as polyethylene glycol (PEG), a
hydrophilic, non-ionic, biocompatible polymer considered the
gold standard in engineering mucus-penetrating surfaces. PEG
grafting reduces adhesion to mucin fibers, allowing nanoparticles
to quickly diffuse through the interstitial fluids enabling sustained
mucosal drug delivery (Huckaby and Lai, 2018). Here, we have
assessed the ability of a standardized cannabis formulation
containing PEG (Trokie R© lozenges) to deliver cannabinoids via
the buccal/oral mucosa as well as associated AEs.
MATERIALS AND METHODS
Research Population
We conducted two observational studies with members of
the Palliative Care Corporation (PCC), a health clinic in
Huntington Beach, CA, which distributes Trokie R© lozenges.
Admission criteria for the health clinic include: (i) willingness
to incorporate cannabis into current medication regime; (ii)
not having known allergies to cannabinoid drugs (dronabinol,
nabilone, nabiximols); (iii) not having a cardiac arrhythmia; and
(iv) not being pregnant. At the time of enrollment, members
were asked to rate their pain on a pain intensity numeric rating
scale (PI-NRS). This study was carried out in accordance with
the principles of the Declaration of Helsinki and followed the
relevant institutional and national guidelines. The study met the
criteria set forth in 45 CFR §46.101(b) (4) and was therefore
exempted from institutional review board (IRB) approval by
Quorum Review IRB (Seattle, WA, United States).
Cannabis Self-Administration Protocol
New members joining PCC, especially if cannabis-naive (which
represent approximately 60%), were instructed on how to
properly self-administer Trokie R© lozenges, embracing the “start
low, go slow” motto proposed by clinicians for the use of herbal
cannabis (MacCallum and Russo, 2018), starting with 1/4th of
a 50 mg CBD lozenge (12.5 mg) two or three times a day for
3 days. After this initial period, members are coached by PCC
clinical personnel on how to slowly adjust their intake of THC
and CBD to achieve optimal symptom relief, with follow-up calls
on days 4, 7, 14, and each time they place a new order, under
the guiding principle of “primum non nocere” (Fitzcharles and
Eisenberg, 2018).
Preparation of Trokie R© Lozenges
The following 4-dose lozenges were available to members at PCC:
50 mg (only CBD), 40 mg (1:1 ratio CBD:THC), 64 mg (1:15
ratio CBD:THC), 120 mg (1:15 ratio CBD:THC), and 120 mg
(only THC). Trokie R© lozenges were prepared as described in
U.S. Patent No. 62/018,484 (Crowley, 2017). After preparation,
batch samples were sent to a third-party laboratory for analysis
(CannaSafe Analytics, Murrieta, CA Unites States). Batches were
quarantined until laboratory results allowed release for packaging
and labeling.
Study 1: Effectiveness of the Delivery
System
On December 2016, members of the PCC with a diagnosis of
chronic non-cancer pain who had been enrolled for at least 12
weeks were invited to participate in a phone interview conducted
by KC. The time frame (1–12 weeks) was selected to maximize
the number of members actively enrolled in the clinic at the time
of the study. Participants were asked: (i) to score their current
pain on a PI-NRS from 0 to 10 (Farrar et al., 2001), (ii) answer
a global self-assessment of feeling better, same or worse, and (iii)
to estimate the onset of analgesia after taking Trokie R© lozenges.
Participants using opiate medication were questioned about any
modifications on their intake from the time of enrollment.
Study 2: Assessment of Adverse Events
To assess the safety of Trokie R© lozenges, we conducted a survey
on February 2018 among PCC members with chronic non-cancer
pain that had been enrolled for a sustained period of time,
between 4 and 60 weeks. This time frame was selected to capture
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AEs associated to mid- to long-term use of Trokie R© lozenges.
Participants were asked to complete a questionnaire to report
adverse drug reactions (de Vries et al., 2013), slightly modified
to focus on AEs caused by Trokie R© lozenges.
Analyses
Pain intensity was calculated as the difference between PI-NRS
values reported on December 2016 and those reported at
enrollment, and it is expressed as mean ± standard deviation
of the mean. Significance of differences was determined using
a paired t-test (PI-NRS before vs. PI-NRS after). Differences
were considered significant if P < 0.05. Statistical analyses were
conducted using GraphPad Prism Version 7.0 (San Diego, CA,
United States). Patient-reported AEs were analyzed descriptively
using IBM SPSS Statistics version 23 (Armonk, New York, NY,
United States).
RESULTS
Study 1: Effectiveness of the Delivery
System
A total of 49 participants (15 males/34 females) with an average
age of 59.9 years completed the study (descriptive statistics
in Supplementary Table 1). An average reduction in PI-NRS
score of 4.9 ± 2.0 points (from 7.4 ± 1.3 to 2.4 ± 1.8) was
observed (Figure 1A). Also, among 31 participants using opiates,
26 (84%) voluntarily reduced or discontinued their use of opiate
FIGURE 1 | Participants using Trokie R© lozenges reported a mean reduction in pain intensity of 4.9 ± 2.0 points (A), from a median value of 7.4 (pre-treatment, dark
blue circles) to 2.4 (post-treatment, light blue diamonds) on an 11-point scale (0 = no pain, 10 = worst pain imaginable). Among 31 participants using opiates, 26
(84%) reduced in some degree or completely discontinued their use of opiate medication (B).
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medication (Figure 1B). These reductions were completed by
participants with no reported symptoms of opiate withdrawal.
Lastly, all participants reported feeling an improvement in their
condition (100%) and an onset of analgesia between 5 and 40 min.
Study 2: Assessment of Adverse Events
The adverse drug reaction questionnaire was completed by a
total of 35 participants (7 males/28 females) with an average age
of 65.3 years (descriptive statistics in Supplementary Table 1).
Twenty AEs were reported by 16 participants (46%), with most
reporting one single AE (N = 12; 75%) and four reporting
two AEs. Descriptions given by participants corresponded to
7 AEs (with some of them relating to more than one AE)
which were: dizziness/unsteadiness (N = 7), bad taste (5),
throat irritation/dry mouth (N = 4), drowsiness/fatigue (N = 3),
impaired consciousness/high feeling (N = 2), nausea (N = 1),
and palpitations (N = 1). There were no reports of damage
to the oral mucosa, gums, or teeth. None of the self-reported
AEs resulted in a serious medical situation and most of them
had only limited impact on daily functioning. Of notice, AEs
associated with CBD-only Trokie R© lozenges were not related to
any psychoactivity and were restricted to bad taste (4) and throat
irritation/dry mouth (2). The remainder of AEs were associated
with THC-containing lozenges, alone or in combination with
opiates or other THC-containing products. Despite these AEs,
90% of participants reported being “satisfied” or “very satisfied”
with the product (Table 1).
DISCUSSION
Trokie R© lozenge is a cannabis-based product currently available
in six states of the Union (Arizona, California, Florida, Iowa,
Nevada, and Minnesota) and Puerto Rico. Two observational
studies were conducted with California-certified cannabis
patients to assess the effectiveness and safety of Trokie R© lozenges.
First, we focused on the effectiveness of Trokie R©lozenges to
deliver cannabinoids, namely THC and CBD, through the
buccal mucosa: does it work in practice? (Haynes, 1999). Our
findings indicate that the use of Trokie R© lozenges is associated
with a self-reported pain reduction in chronic, non-cancer
pain patients, a condition for which the efficacy of cannabis
has been previously described (Lynch and Ware, 2015). Of
note, reported time to onset was between 5 and 40 min
which, considering lozenges take 20–25 min to dissolve, seems
consistent with, at least partial, buccal absorption (Karschner
et al., 2011). However, it is reasonable to assume that it can
also be swallowed with saliva. Correct placement in the mouth
appeared to be critical for minimizing saliva production. Next,
we aimed at assessing the safety of Trokie R© lozenges and
the kind of AEs that could be associated with its long-term
use: is it safe to use? Seven different AEs were reported by
participants, one of them related to the organoleptic qualities
of the product (bad taste) and the rest being common to
other cannabis products containing THC, such as dizziness
or dry mouth, none of which resulted in a serious medical
situation and only had limited impact on daily functioning.
TABLE 1 | Nature of the reported adverse events (AEs).
N (%)
First time experiencing the AE
Today 0 (0)
Yesterday 0 (0)
2–7 days ago 0 (0)
Between 1 week and 1 month ago 0 (0)
Between 1 and 6 months ago 1 (5)
Between 6 and 12 months ago 3 (15)
More than 12 months ago 16 (80)
How much bothersome
Not at all 0 (0)
Only a bit 7 (35)
Somewhat 6 (30)
Quite a lot 6 (30)
Very much 1 (5)
Influence daily functioning
None 10 (50)
Only a bit 4 (20)
Somewhat 2 (10)
Quite a lot 3 (15)
Very much 1 (5)
Drug causing the AE
One drug, namely: 18 (90)
Trokie R© lozenges CBD 6
Trokie R© lozenges CBD and THC 5
Trokie R© lozenges THC 7
More than one drug 2 (10)
Trokie R© lozenges THC + Opiates 1
Trokie R© lozenges THC + THC capsules 1
Participants’ certainty about the relationship between the reported AE
and Trokie R©
Very sure 18 (90)
Quite sure 2 (10)
Not very sure 0 (0)
Very unsure 0 (0)
Satisfaction with Trokie R© lozenges
Very satisfied 9 (45)
Satisfied 9 (45)
Neither satisfied or dissatisfied 0 (0)
Dissatisfied 1 (5)
Very dissatisfied 1 (5)
Interestingly, our results are in strong agreement with a recent
study performed in Israel on a large cohort of elderly (over
900 participants, 74.5 ± 7.5 years) reporting a reduction of
pain levels from a median of 8 to a median of 4 on a
scale of 0–10 after 6 months of cannabis treatment. Further,
most common AEs were dizziness (10%), dry mouth (7%),
and 18% of participants stopped using opiate analgesics or
reduced their dose (Abuhasira et al., 2018). In our case, the
proportion of participants reducing or discontinuing opiate
analgesics was significantly larger (84%), similar to what
has been previously found in a study based on patient
self-reports (Reiman et al., 2017). This may be explained
Frontiers in Neuroscience | www.frontiersin.org 4 August 2018 | Volume 12 | Article 564
fnins-12-00564 August 11, 2018 Time: 17:24 # 5
Crowley et al. Standardized Buccal Delivery of Cannabis
by the extensive use of opiate medication in the United States and
the fact that many PCC members are seeking cannabis treatment
because they “want to get off opiates and don’t want to get high”
(personal communications with PCC staff).
Legalization of medical and recreational cannabis has
bypassed the usual drug regulatory procedures in jurisdictions
worldwide. Pending sound evidence for its effects in many
conditions, physicians face the challenge of continuing to
provide competent, compassionate care with an emphasis in
harm reduction. Nevertheless, this regulatory scenario creates
unprecedented opportunities to study the clinical impact of
cannabinoids in human health and behavior. An illustrative
example of how commodities can revolutionize the way we
perform biomedical research are consumer physical activity
monitors, which have raised enormous interest to physiology
and psychopathology research because of their ability to measure
activity continuously under real-life conditions and because they
are already widely used by consumers (Wright et al., 2017).
We believe the present results provide valuable information
in terms of route validation, dosage selection and expected
AEs, while cognizant of the severe limitations of our design
due to the nature of the research, such as biased participant
selection, lack of blinding or absence of placebo control.
Therefore, these results should not be interpreted to establish
any causality between the use of Trokie R© lozenges and the
improvement in participants well-being. However, the findings
support the need for conducting a phase 1 clinical trial to formally
characterize the pharmacokinetic profile of Trokie R© lozenges in
humans.
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